CLIA Kit for Interleukin 33 (IL33) Homo sapiens (Human) Sandwich CLIA

DV27; C9ORF26; IL1F11; NFHEV; Interleukin-1 Family, Member 11; Nuclear factor from high endothelial venules

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • CLIA Kit for Interleukin 33 (IL33) Packages (Simulation)
  • CLIA Kit for Interleukin 33 (IL33) Packages (Simulation)
  • CLIA Kit for Interleukin 33 (IL33) Results demonstration
  • SCB980Hu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Interleukin 33 (IL33) and the recovery rates were calculated by comparing the measured value to the expected amount of Interleukin 33 (IL33) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 79-105 102
EDTA plasma(n=5) 85-104 95
heparin plasma(n=5) 98-105 102

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Interleukin 33 (IL33) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Interleukin 33 (IL33) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Interleukin 33 (IL33) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 92-101% 90-104% 88-101% 80-104%
EDTA plasma(n=5) 88-95% 84-101% 88-101% 78-105%
heparin plasma(n=5) 82-96% 97-104% 81-97% 98-105%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Substrate A 1×10mL Substrate B 1×2mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

CLIA Kit for Interleukin 33 (IL33)

Test principle

The microplate provided in this kit has been pre-coated with an antibody specific to Interleukin 33 (IL33). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Interleukin 33 (IL33). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Interleukin 33 (IL33) level in the sample or standard.;

Citations

  • Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarctionPubMed: PMC3604606
  • CXCL13 blockade attenuates lupus nephritis of MRL/lpr micePubMed: 26456520
  • Epithelial Cell-Derived Cytokines Contribute to the Pathophysiology of Eosinophilic Chronic RhinosinusitisPubmed:26540312
  • The Expression and Regulation of Interleukin-33 in Human Epidermal Keratinocytes: A New Mediator of Atopic Dermatitis and Its Possible Signaling Pathway.pubmed:27348082
  • IL-33 circulating serum levels are increased in patients with non-segmental generalized vitiligopubmed:27388717
  • Chrysin Protects Rat Kidney from Paracetamol-Induced Oxidative Stress, Inflammation, Apoptosis, and Autophagy: A Multi-Biomarker Approach. pubmed:28134775
  • Association of IL-33, IL1RL1 gene polymorphisms with serum IL-33 levels and risk of asthma in adults and asthmatic bronchitis in children (Chinese)10.1080:13102818.2018.1471361
  • Role of IL-33 and ST2 signaling and inflammatory responses in non-small cell lung cancer172341
  • Group II innate lymphoid cells and microvascular dysfunction from pulmonary titanium dioxide nanoparticle exposurePubmed: 30413212
  • Interleukin-33 serum levels in postmenopausal women with osteoporosisPubmed: 30846811
  • Tumor-Derived Lactic Acid Contributes to the Paucity of Intratumoral ILC2sPubmed: 32101749
  • Relationship of microbial profile with airway immune response in eosinophilic or neutrophilic inflammation of asthmaticsPubmed: 32141256
  • Qingfei oral liquid downregulates TRPV1 expression to reduce airway inflammation and mucus hypersecretion injury caused by respiratory syncytial virus infection …
  • Aggravation of Airway Inflammation in RSV-Infected Asthmatic Mice Following Infection-Induced Alteration of Gut Microbiota
  • Inhibition of NF-κB/IL-33/ST2 Axis Ameliorates Acute Bronchiolitis Induced by Respiratory Syncytial Virus34395633
  • Elevated Levels of IL-33, IL-17 and IL-25 Indicate the Progression from Chronicity to Hepatocellular Carcinoma in Hepatitis C Virus PatientsPubmed:35056005
  • Dexmedetomidine Attenuates Hyperalgesia Induced By Brachial Plexus Root Avulsion By Restoring The GLT-1 Function Via PKA Signaling

Recommend products